Results 251 to 260 of about 233,764 (324)

Comparative Analysis of Drug-Induced Sleep Endoscopy With Positive Airway Pressure and Therapeutic Continuous Positive Airway Pressure in the Treatment of Obstructive Sleep Apnea. [PDF]

Laryngoscope Investig Otolaryngol
Sina EM, Molin N, Kaki PC, Ideker H, White S, Boon M, Huntley C.   +6 more
europepmc   +1 more source

Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT‐2 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim To assess the efficacy and safety of once‐weekly tirzepatide in Japanese participants with obesity and type 2 diabetes (T2D). Materials and Methods This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT‐2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle ...
Toshimasa Yamauchi, Taro Asakura, Tomotaka Shingaki, Tomonori Oura, Hideki Katagiri   +4 more
wiley   +1 more source

The association of the non-HDL-cholesterol to HDL-cholesterol ratio (NHHR) with obstructive sleep apnea among adults aged ≥ 40 years: results from NHANES 2015-2018. [PDF]

BMC Public Health
Chen L, Chen J, Chen S, Cui Y.
europepmc   +1 more source

Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT‐2 and STEP 2.
Andreea Ciudin, Erin Johansson, Sarah Zimner‐Rapuch, Georgios K. Dimitriadis, Marine Bertrand, Tristan Curteis, Laura J. Clark, Ludi Fan, Helene Sapin, Jean‐Francois Bergmann   +9 more
wiley   +1 more source

Prevalence and characteristics of rapid eye movement-related sleep apnea in a population-based cohort. [PDF]

Ann Thorac Med
Kanbr O, Wali S, Wasfi L, Sharif A, Batawi G, Manzar MD, Alshumrani R, Alhejaili F.   +7 more
europepmc   +1 more source

Socio‐demographic and clinical factors associated with the receipt of anti‐obesity medication prescriptions and metabolic and bariatric surgery among eligible all of Us participants

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims There is a paucity of data on socio‐economic characteristics associated with the use of anti‐obesity medications (AOM) and metabolic and bariatric surgery (MBS) when accounting for clinical factors. This study characterized factors associated with the receipt of AOM prescriptions and MBS.
Olajide A. Adekunle, Phuc Le, Dev Yash Gupta, Michael B. Rothberg, Ha T. Tran, Yihua Yue, Hamlet Gasoyan   +6 more
wiley   +1 more source

Association between tear lactoferrin, lysozyme, albumin levels, and obstructive sleep apnea syndrome: a cross-sectional study. [PDF]

Front Med (Lausanne)
Wang B, Hong C, Li W.
europepmc   +1 more source

Real‐world insights into incretin‐based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross‐sectional study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This cross‐sectional study examined associations between self‐reported taste perception changes and appetite‐related outcomes in individuals with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RAS) or dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 RAS in real‐world conditions.
Ali Kapan, Othmar Moser, Richard Felsinger, Thomas Waldhoer, Sandra Haider   +4 more
wiley   +1 more source

Gait Characteristics and Neuroanatomical Alterations in Obstructive Sleep Apnea-Hypopnea Syndrome. [PDF]

Nat Sci Sleep
Jiang J, Mo Y, Abuduwaili Z, Mao C, Fang S, Ke Z, Hu Z, Huang L, Xu S, Yang D, Xiong R, Xie P, Zhu X, Xu Y.   +13 more
europepmc   +1 more source

Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Globally, cardiovascular diseases (CVDs) account for around one‐third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon‐like peptide‐1 (GLP‐1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all‐cause ...
Naveed Sattar, Luis‐Emilio García‐Pérez, Angel Rodríguez, Richa Kapoor, Adam Stefanski, Emily R. Hankosky   +5 more
wiley   +1 more source